Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Phase 2 Completed 47 enrolled M.D. Anderson Cancer Center Amgen · collab Celgene Corporation · collab

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn how effective the combination of chemotherapy including both panitumumab, Abraxane (nab-paclitaxel), and carboplatin (PNC) and fluorouracil, epirubicin, and cyclophosphamide (FEC) used before surgery for the treatment of IBC is. The safety of PNC combination will also be studied.

Timeline

Start: 2010-11
Primary completion: 2016-02-11
Completion: 2022-08-09

Publications

Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez RH, Willey JS, Parker CA, Song J, Shen Y, Hu J, Wu W, Li N, Babiera GV, Murray JL, Arun BK, Brewster AM, Reuben JM, Stauder MC, Barnett CM, Woodward WA, Le-Petross HTC, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT. Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol. 2018 Sep 1;4(9):1207-1213. doi: 10.1001/jamaoncol.2018.1436.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	2 unknown	Intravenous
Subject	Cyclophosphamide	Other / unclassified	500 mg/m2	Intravenous
Subject	Epirubicin	Small molecule	100 mg/m2	Intravenous
Subject	Nab-paclitaxel	Small molecule	100 mg/m2	Intravenous
Subject	Panitumumab	Monoclonal antibody	2.5 mg/kg	Intravenous
Subject	fluorouracil	Small molecule	500 mg/m2	Intravenous

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Summary

Timeline

Publications

Drugs

Indications